Current status of immunosuppressive agents for solid organ transplantation in children.

Anil Dhawan, Tracy Coelho, Michael Tredger

Journal: Pediatric transplantation 2012;16(2):106-22

PMID: 22360399

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Immunosuppression after organ transplantation is complex and ever evolving. Over the past two decades, newer immunosuppressive agents have been introduced with an aim to provide better patient and graft survival. Improved therapeutic strategies have been developed offering the option to use combinations of drugs with non-overlapping toxicities. There are, however, only a few clinical studies with robust data to rationalize the use of these agents in children. This review will discuss the newer immunosuppressive agents used for solid organ transplant, their current status in post-transplant management and prevention of allograft rejection.

Address: Paediatric Liver GI and Nutrition Centre, King's College Hospital, King's College London School of Medicine, London, UK.

DOI: 10.1111/j.1399-3046.2012.01644.x

Link outs

Free resources

Medical:

https://medlineplus.gov/organtransplantation.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

MeSH Terms: Alemtuzumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antilymphocyte Serum, Basiliximab, Child, Daclizumab, Everolimus, Graft Rejection, Humans, Immunoglobulin G, Immunosuppressive Agents, Muromonab-CD3, Mycophenolic Acid, Organ Transplantation, Recombinant Fusion Proteins, Sirolimus, Tacrolimus